======================================================================
 ORACLE FORMULATION OPTIMIZATION REPORT
======================================================================

 DRUG CANDIDATE:
   Name: Oracle-TNBC-001
   SMILES: CC(C)C1=C(NC(=O)NS(C)(=O)=O)c2c(ccc3ccccc23)C1C
   Formula: C19H32N2O3S1
   MW: 368.54 Da
   Predicted Affinity: -8.791 kcal/mol

 PHYSICOCHEMICAL PROPERTIES:
   Property                  Value           Status
   -------------------------------------------------------
   Molecular Weight          368.5 Da         ✓ Good
   Estimated logP            -0.45             ⚠️ Suboptimal
   H-Bond Donors             5               ✓ Good
   H-Bond Acceptors          5               ✓ Good
   TPSA (estimated)          112 Ų           ⚠️ High
   Rotatable Bonds           4               ✓ Good

 BLOOD-BRAIN BARRIER ASSESSMENT:
   BBB Score: 35/100
   Native BBB Permeability: ✗ NO
   → NANOPARTICLE FORMULATION REQUIRED FOR BRAIN DELIVERY

 CYP450 INHIBITION RISK:
   Risk Level: LOW

 TARGET INDICATION:
   Triple-Negative Breast Cancer
   Brain Metastasis Risk: HIGH
   • High rate of brain metastasis (25-46%)
   • No targeted therapy available
   • Aggressive phenotype

 FORMULATION RATIONALE:
   ⚠️ Drug has LOW BBB permeability (score: 35/100)
      → Nanoparticle formulation REQUIRED for brain metastasis treatment
   ⚠️ High TPSA (112 Å²) limits passive diffusion
   🎯 Triple-Negative Breast Cancer has HIGH brain metastasis risk
      → BBB-penetrating formulation strongly recommended
   
✅ TOP RECOMMENDATION: PEGylated Liposome (Doxil-type)
      • Proven clinical track record (Doxil, Onivyde)
      • Strong EPR effect - accumulates in tumors
      • Reduces systemic toxicity

 RANKED FORMULATION STRATEGIES:
   Rank  Score    Formulation                         BBB
   ------------------------------------------------------------
   1     100/100    PEGylated Liposome (Doxil-type)     ✓
   2     100/100    Transferrin-Modified Liposome       ✓
   3     100/100    Polymeric Micelle                   ✓
   4     50/100    Ionizable Lipid Nanoparticle (LNP   ✗
   5     50/100    PLGA Nanoparticle                   ✗

======================================================================
 RECOMMENDED FORMULATION: PEGylated Liposome (Doxil-type)
======================================================================

 Description: Lipid bilayer vesicles with PEG coating for extended circulation
 Particle Size: 80-120 nm
 BBB Compatible: Yes
 EPR Effect: Yes

 ADVANTAGES:
   ✓ Proven clinical track record (Doxil, Onivyde)
   ✓ Strong EPR effect - accumulates in tumors
   ✓ Reduces systemic toxicity
   ✓ PEG coating extends circulation half-life
   ✓ Can be modified for BBB penetration

 KEY COMPONENTS:
   • DSPC (distearoylphosphatidylcholine)
   • Cholesterol (membrane stabilizer)
   • DSPE-PEG2000 (PEGylated lipid, ~5 mol%)
   • Optional: Targeting ligand (transferrin, folate)

 PREPARATION METHOD:
   Thin-film hydration or ethanol injection

 CLINICAL PRECEDENTS:
   • Doxil (doxorubicin)
   • Onivyde (irinotecan)
   • Marqibo (vincristine)

----------------------------------------------------------------------
 LIPOSOME BATCH CALCULATION (10 mg drug)
----------------------------------------------------------------------

 Lipid Composition (molar ratio):
   DSPC : Cholesterol : DSPE-PEG2000 = 0.56 : 0.39 : 0.05

 For 10 mg drug batch:
   DSPC: 120.06 mg (0.1520 mmol)
   Cholesterol: 40.92 mg (0.1058 mmol)
   DSPE-PEG2000: 38.06 mg (0.0136 mmol)

   Total lipid: 199.04 mg
   Hydration volume: 2.7 mL

 Process:
   Buffer: 10 mM HEPES, 150 mM NaCl, pH 7.4
   Extrusion: 10x through 100 nm polycarbonate
   Target size: 100 nm

======================================================================
 SUMMARY
======================================================================

 BEFORE FORMULATION:
   • BBB Permeant: NO ❌
   • Brain Mets Efficacy: INEFFECTIVE ❌
   • CYP450 Risk: LOW
   
 AFTER NANOPARTICLE FORMULATION:
   • BBB Permeant: YES ✓ (via transcytosis/EPR)
   • Brain Mets Efficacy: ENABLED ✓
   • CYP450 Risk: REDUCED ✓ (drug sequestered from liver)
   • Tumor Selectivity: ENHANCED ✓ (EPR effect)

======================================================================
